ARTICLE | Company News
Arrowhead endocrine news
April 11, 2011 7:00 AM UTC
Arrowhead increased its stake in its Ablaris Therapeutics Inc. subsidiary to 64% from 55% after investing an additional $800,000 in the subsidiary in the second and final closing of a series A round. ...